# EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease

> **NIH NIH N44** · SILVER LAKE RESEARCH CORPORATION · 2023 · $750,000

## Abstract

Silver Lake proposes to fully characterize mAb against 6 targets produced in their three concurrent Phase 1 projects that are relevant in models of disease and inflammation, determine their usability in multiple assay types, develop user protocols for each assay type and mAb, produce quality-controlled reagents, produce multiple conjugates for each mAb, and make all reagents available for the research community.

## Key facts

- **NIH application ID:** 10933282
- **Project number:** 75N93023C00039-0-9999-1
- **Recipient organization:** SILVER LAKE RESEARCH CORPORATION
- **Principal Investigator:** MARK GEISBERG
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $750,000
- **Award type:** —
- **Project period:** 2023-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10933282

## Citation

> US National Institutes of Health, RePORTER application 10933282, EAP-Derived Monoclonal Antibodies for Phenotyping Immune Cells of Animal Model of Disease (75N93023C00039-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10933282. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*